Business Context and Reporting Period
This Form 8-K was filed by Altimmune, Inc. on March 14, 2019. The report discloses an amendment to the consulting agreement with Will Brown, the Company's Acting Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
Material Changes
The primary material change is the amendment to Mr. Brown's consulting agreement effective March 14, 2019. The amendment establishes specific compensation triggers if Mr. Brown is not appointed as full-time Chief Financial Officer by July 1, 2019.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or general management commentary regarding business operations. It details the following compensation contingencies:
- Monthly Fee: If not appointed full-time CFO by July 1, 2019, Mr. Brown will receive $35,400 per full month for continued services.
- Termination Payment: If the Company terminates the engagement without "Cause" on or after July 1, 2019, Mr. Brown is eligible for a payment of $84,000, subject to signing a general release of claims.
Investor Verification Checklist
- Verify the appointment status of Will Brown as full-time CFO prior to the July 1, 2019 deadline.
- Review the full text of the Amendment (Exhibit 10.1) for the specific definition of "Cause" regarding termination.
- Confirm whether the $84,000 termination payment is contingent solely on the release of claims or includes other conditions.